JNJ-70218902
- Generic Name
- JNJ-70218902
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Phase 1
- Conditions
- Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-HodgkinMyelodysplastic SyndromesNeoplasmsSolid Tumor, AdultMetastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2025-01-23
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06788509
- Locations
- 🇨🇳
Chang Kung Memorial Hospital, Kaohsiung City, Taiwan
🇧🇪Ghent University Hospital, Gent, Belgium
🇫🇷Hopital Claude Huriez, Lille, France
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 82
- Registration Number
- NCT04397276
- Locations
- 🇨🇦
BC Cancer Agency - Vancouver BC, Vancouver, British Columbia, Canada
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
🇮🇱Rambam Medical Center, Haifa, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath